March 17 Amgen Inc said on Monday its
experimental new type of cholesterol fighter met the primary
goal of a late-stage trial by significantly cutting "bad" LDL
cholesterol among patients with a genetic tendency towards very
high levels of the artery clogging fat.
Amgen said patients given its injectable drug evolocumab
once a month on top of standard daily statin treatments showed
"clinically meaningful" improvement compared to statins alone
after 12 weeks of treatment.
Evolocumab works by blocking PCSK9, a naturally occurring
protein that keeps LDL levels elevated in the bloodstream. Other
drugmakers, including Pfizer Inc and a partnership
between Regeneron Inc and Sanofi, are racing
with Amgen to complete trials of potentially lucrative